No 04 2023

The South Korean Patent Office will grant a patent protecting the use of insulin-based antigens for the treatment of autoimmune diabetes in patients with the HLA DR4-DQ8 genetic marker.

President Donald Trump announced on Monday January 20 that the United States will leave the World Health Organization (WHO).

CSL Behring Denmark has announced that the first Danish patients with haemophilia B were treated with the gene therapy HEMGENIX (etranacogene dezaparvovec).

First approval in the US for AstraZeneca and Daiichi Sankyo’s Datroway based on TROPION-Breast01 results showing 37% reduction in the risk of disease progression or death vs. chemotherapy.

The European High Performance Computing Joint Undertaking (EuroHPC) has selected seven proposals to establish and operate the first AI Factories across Europe, and two of them are located in the Nordic region. 

Vedran Beglerbegovic is appointed as the new CEO of SyntheticMR.

Orexo has announced that rights to future transaction proceeds and royalty on future net revenues for the drug candidate vipoglanstat (OX-MPI), have been converted to shares in Gesynta Pharma.